AlphAIAlphAI — Financial news for AI agents
Stock TitanMAY 143 min read$GRI

GRI Bio (GRI) Schedule 13G/A: 90,475 shares represent 5.9% stake

GRI Bio, Inc. has filed an Amendment No. 2 to a Schedule 13G/A, reporting that Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC beneficially own 90,475 shares of common stock, representing a 5.9% stake. These shares are issuable upon the exercise of a warrant held by Intracoastal, based on 1,445,029 shares outstanding as of January 29, 2026. The filing notes two additional warrants with 4.99% blocker provisions, which are excluded from this reported percentage.

Original reporting
Stock Titan
Published May 14, 2026, 4:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 14, 2026, 4:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$GRI
Bullish
medium confidence
Mentioned
$GRI
Relevance
6/10
AlphAI data visualization · based on Stock Titan
Decision brief

The 30-second read

$GRIBullishMed
01

Why it matters

This ownership change could signal positive sentiment, possibly leading to short-term price appreciation.

02

Market read

While relevant within biotech investment circles, the overall market impact remains limited due to the company's size and sector.

03

What to watch

Potential dilution effects from warrants and options not exercised yet could offset ownership gains.

Relevance 6/10Timing: short-term (within 1-2 weeks)

Background

GRI Bio filed an amended Schedule 13G/A revealing increased ownership by institutional investors, indicating confidence.

Company-level read

Ticker impact

$GRIBullishMedium confidence
Context

The filing indicates a significant passive stake increase by notable investors, which could influence market perception.

Expected impact

Moderate upward price movement expected over the short to medium term.

Evidence & confidence

Ownership changes by institutional investors often signal confidence, but the lack of recent price action data limits certainty.

Market effects

Sector

Potential positive sentiment in biotech and life sciences sectors due to increased investor confidence.

Regional

Limited regional impact; primarily relevant to US markets where GRI operates.

Global

Minimal; GRI is a niche biotech firm with limited global influence.

Counterpoint

What could challenge this read

The ownership increase may be a defensive move or a sign of insider accumulation without broader positive implications.

Key entities

  • Investor
    Mitchell P. Kopin

    Beneficial owner of shares.

  • Investor
    Daniel B. Asher

    Beneficial owner of shares.

  • Institutional Investor
    Intracoastal Capital LLC

    Holder of warrants and shares.

Read at source← All news

Related articles

AUG 24
$PMIMed

Biotech Gainers: PMI Revenue Growth, SDOT Earnings Surge, CAPR FDA Update, GRI Data Drive Gains

Picard Medical (PMI) rose 40% after reporting Q2 revenue growth of 39% to $3.0M. Sadot Group (SDOT) surged 100% despite zero revenue, with net income up to $35.2M. Capricor Therapeutics (CAPR) gained 11% after FDA extended review for deramiocel. GRI Bio (GRI) climbed 10% with Phase 2a data selected for ERS 2026. Biomea Fusion (BMEA) rose 14% after completing Phase 2 diabetes trial enrollment. Yarrow Bioscience (YARW) advanced 12% with Graves' disease trial updates.

rttnews.com3 min
JUN 18
$GRIMed

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

GRI Bio (NASDAQ: GRI) said the FDA granted Orphan Drug Designation to GRI-0621 (tazarotene) for idiopathic pulmonary fibrosis (IPF). The company noted the designation may provide up to seven years of U.S. market exclusivity after approval, plus potential tax credits and fee waivers. GRI-0621 is an oral RARβ/γ agonist; a Phase 2a trial in 35 patients met endpoints, per the company.

manilatimes.net3 min
OCT 28
$FWRDMed

Forward Air Announces Two-Year Definitive Agreement to Retain Significant Portion of Previously Disclosed Customer Relationship

FORWARD AIR CORP (FWRD) filed an SEC Form 8-K — Other Events. Forward Air Announces Two-Year Definitive Agreement to Retain Significant Portion of Previously Disclosed Customer Relationship 2026 to 2028 Forecasted Annual Revenue from Customer Expected to Exceed 2025 Revenue Driven by Growth in Retained Services DALLAS – October 28, 2026 – F

SEC EDGAR 8-K4 min
OCT 28
$PYPDMedAI 8/10

PolyPid unveils PD01B for diabetic foot infection treatment

PolyPid Ltd. (NASDAQ:PYPD) introduced PD01B, a product candidate for treating moderate to severe diabetic foot infections, using its Kynatrix delivery technology. The company plans to initiate a first-in-human study in the second half of 2027. PolyPid also expects a decision on its lead product D-PLEX₁₀₀ by November 28, 2026, with a potential U.S. launch in early 2027, subject to FDA approval.

investing.com2 min
OCT 28
$KTOSMed

Kratos wins $33.6 million NASA power system contract

Kratos Defense & Security Solutions (KTOS) won a $33.6M contract from NASA to design and build a power system for the Space Reactor-1 Freedom spacecraft, launching in 2028. Kratos will work as a subcontractor to Sierra Lobo under NASA’s SpaceDOC III contract, providing a power conversion system for the mission to Mars. The spacecraft aims to demonstrate nuclear electric propulsion technology. According to the company, the contract is a significant milestone in advancing space nuclear propulsion.

investing.com3 min